tetano
Editor, Senior Moderator
Cell
. 2021 Feb 18;S0092-8674(21)00222-1.
doi: 10.1016/j.cell.2021.02.033. Online ahead of print.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Piyada Supasa[SUP] 1 [/SUP], Daming Zhou[SUP] 2 [/SUP], Wanwisa Dejnirattisai[SUP] 1 [/SUP], Chang Liu[SUP] 3 [/SUP], Alexander J Mentzer[SUP] 4 [/SUP], Helen M Ginn[SUP] 5 [/SUP], Yuguang Zhao[SUP] 2 [/SUP], Helen M E Duyvesteyn[SUP] 2 [/SUP], Rungtiwa Nutalai[SUP] 1 [/SUP], Aekkachai Tuekprakhon[SUP] 1 [/SUP], Beibei Wang[SUP] 1 [/SUP], Guido C Paesen[SUP] 2 [/SUP], Jose Slon-Campos[SUP] 1 [/SUP], C?sar L?pez-Camacho[SUP] 1 [/SUP], Bassam Hallis[SUP] 6 [/SUP], Naomi Coombes[SUP] 6 [/SUP], Kevin R Bewley[SUP] 6 [/SUP], Sue Charlton[SUP] 6 [/SUP], Thomas S Walter[SUP] 2 [/SUP], Eleanor Barnes[SUP] 7 [/SUP], Susanna J Dunachie[SUP] 8 [/SUP], Donal Skelly[SUP] 9 [/SUP], Sheila F Lumley[SUP] 10 [/SUP], Natalie Baker[SUP] 6 [/SUP], Imam Shaik[SUP] 6 [/SUP], Holly E Humphries[SUP] 6 [/SUP], Kerry Godwin[SUP] 6 [/SUP], Nick Gent[SUP] 6 [/SUP], Alex Sienkiewicz[SUP] 6 [/SUP], Christina Dold[SUP] 11 [/SUP], Robert Levin[SUP] 12 [/SUP], Tao Dong[SUP] 13 [/SUP], Andrew J Pollard[SUP] 11 [/SUP], Julian C Knight[SUP] 14 [/SUP], Paul Klenerman[SUP] 7 [/SUP], Derrick Crook[SUP] 15 [/SUP], Teresa Lambe[SUP] 16 [/SUP], Elizabeth Clutterbuck[SUP] 11 [/SUP], Sagida Bibi[SUP] 11 [/SUP], Amy Flaxman[SUP] 16 [/SUP], Mustapha Bittaye[SUP] 16 [/SUP], Sandra Belij-Rammerstorfer[SUP] 16 [/SUP], Sarah Gilbert[SUP] 16 [/SUP], David R Hall[SUP] 5 [/SUP], Mark A Williams[SUP] 5 [/SUP], Neil G Paterson[SUP] 5 [/SUP], William James[SUP] 17 [/SUP], Miles W Carroll[SUP] 18 [/SUP], Elizabeth E Fry[SUP] 2 [/SUP], Juthathip Mongkolsapaya[SUP] 19 [/SUP], Jingshan Ren[SUP] 20 [/SUP], David I Stuart[SUP] 21 [/SUP], Gavin R Screaton[SUP] 22 [/SUP]
Affiliations
Abstract
SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of the pandemic and error-prone virus replication is leading to the appearance of mutant viruses and potentially escape from antibody responses. Variant B.1.1.7, now dominant in the UK, with increased transmission, harbors 9 amino acid changes in the spike, including N501Y in the ACE2 interacting surface. We examine the ability of B.1.1.7 to evade antibody responses elicited by natural SARS-CoV-2 infection or vaccination. We map the impact of N501Y by structure/function analysis of a large panel of well-characterized monoclonal antibodies. B.1.1.7 is harder to neutralize than parental virus, compromising neutralization by some members of a major class of public antibodies through light-chain contacts with residue 501. However, widespread escape from monoclonal antibodies or antibody responses generated by natural infection or vaccination was not observed.
Keywords: B.1.1.7; IGHV3-53; Kent; SARS-CoV-2; antibody; escape; neutralization; variant.
. 2021 Feb 18;S0092-8674(21)00222-1.
doi: 10.1016/j.cell.2021.02.033. Online ahead of print.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Piyada Supasa[SUP] 1 [/SUP], Daming Zhou[SUP] 2 [/SUP], Wanwisa Dejnirattisai[SUP] 1 [/SUP], Chang Liu[SUP] 3 [/SUP], Alexander J Mentzer[SUP] 4 [/SUP], Helen M Ginn[SUP] 5 [/SUP], Yuguang Zhao[SUP] 2 [/SUP], Helen M E Duyvesteyn[SUP] 2 [/SUP], Rungtiwa Nutalai[SUP] 1 [/SUP], Aekkachai Tuekprakhon[SUP] 1 [/SUP], Beibei Wang[SUP] 1 [/SUP], Guido C Paesen[SUP] 2 [/SUP], Jose Slon-Campos[SUP] 1 [/SUP], C?sar L?pez-Camacho[SUP] 1 [/SUP], Bassam Hallis[SUP] 6 [/SUP], Naomi Coombes[SUP] 6 [/SUP], Kevin R Bewley[SUP] 6 [/SUP], Sue Charlton[SUP] 6 [/SUP], Thomas S Walter[SUP] 2 [/SUP], Eleanor Barnes[SUP] 7 [/SUP], Susanna J Dunachie[SUP] 8 [/SUP], Donal Skelly[SUP] 9 [/SUP], Sheila F Lumley[SUP] 10 [/SUP], Natalie Baker[SUP] 6 [/SUP], Imam Shaik[SUP] 6 [/SUP], Holly E Humphries[SUP] 6 [/SUP], Kerry Godwin[SUP] 6 [/SUP], Nick Gent[SUP] 6 [/SUP], Alex Sienkiewicz[SUP] 6 [/SUP], Christina Dold[SUP] 11 [/SUP], Robert Levin[SUP] 12 [/SUP], Tao Dong[SUP] 13 [/SUP], Andrew J Pollard[SUP] 11 [/SUP], Julian C Knight[SUP] 14 [/SUP], Paul Klenerman[SUP] 7 [/SUP], Derrick Crook[SUP] 15 [/SUP], Teresa Lambe[SUP] 16 [/SUP], Elizabeth Clutterbuck[SUP] 11 [/SUP], Sagida Bibi[SUP] 11 [/SUP], Amy Flaxman[SUP] 16 [/SUP], Mustapha Bittaye[SUP] 16 [/SUP], Sandra Belij-Rammerstorfer[SUP] 16 [/SUP], Sarah Gilbert[SUP] 16 [/SUP], David R Hall[SUP] 5 [/SUP], Mark A Williams[SUP] 5 [/SUP], Neil G Paterson[SUP] 5 [/SUP], William James[SUP] 17 [/SUP], Miles W Carroll[SUP] 18 [/SUP], Elizabeth E Fry[SUP] 2 [/SUP], Juthathip Mongkolsapaya[SUP] 19 [/SUP], Jingshan Ren[SUP] 20 [/SUP], David I Stuart[SUP] 21 [/SUP], Gavin R Screaton[SUP] 22 [/SUP]
Affiliations
- PMID: 33743891
- DOI: 10.1016/j.cell.2021.02.033
Abstract
SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of the pandemic and error-prone virus replication is leading to the appearance of mutant viruses and potentially escape from antibody responses. Variant B.1.1.7, now dominant in the UK, with increased transmission, harbors 9 amino acid changes in the spike, including N501Y in the ACE2 interacting surface. We examine the ability of B.1.1.7 to evade antibody responses elicited by natural SARS-CoV-2 infection or vaccination. We map the impact of N501Y by structure/function analysis of a large panel of well-characterized monoclonal antibodies. B.1.1.7 is harder to neutralize than parental virus, compromising neutralization by some members of a major class of public antibodies through light-chain contacts with residue 501. However, widespread escape from monoclonal antibodies or antibody responses generated by natural infection or vaccination was not observed.
Keywords: B.1.1.7; IGHV3-53; Kent; SARS-CoV-2; antibody; escape; neutralization; variant.